Pricing Log in Create free account

Pliant Therapeutics, Inc. (PLRX) vs Xilio Therapeutics, Inc. (XLO)

Pliant Therapeutics, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Pliant Therapeutics, Inc. and Xilio Therapeutics, Inc. are of similar size ($60.2M and $59.4M). Xilio Therapeutics, Inc. grew revenue faster over the last twelve months: 327.3% against −49.0%. Pliant Therapeutics, Inc. has the higher net margin (0.00% vs −34.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Pliant Therapeutics, Inc. leads on 8 and Xilio Therapeutics, Inc. on 7.

Valuation

Metric PLRX XLO Biotechnology median
P/E n/m n/m 8.50
P/S 11.09 2.66 9.71
P/B 0.38 2.36 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.76 n/m 0.64
EV/Sales (14.31) 0.56 9.21
Earnings yield (165.56%) (17.00%) (33.15%)
Free cash flow yield (126.73%) (36.00%) (25.50%)

Profitability

Metric PLRX XLO Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (48.94%) 0.00%
Net margin 0.00% (34.06%) 0.00%
Free cash flow margin 0.00% (95.59%) 0.00%
Return on equity (50.29%) (55.03%) (56.36%)
Return on assets (37.69%) (15.16%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PLRX XLO Biotechnology median
Revenue growth (TTM) (48.95%) 327.25% 6.02%
EPS growth (last fiscal year) 29.97% 72.55% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PLRX XLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.90 4.25 4.72
Net debt to EBITDA 1.27 3.40 0.96

Dividend

Metric PLRX XLO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric PLRX XLO Biotechnology median
Market cap 60.21m 59.35m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack